Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Parasit Vectors ; 15(1): 329, 2022 Sep 19.
Article in English | MEDLINE | ID: mdl-36123705

ABSTRACT

BACKGROUND: An innovative approach has been introduced for identifying and developing novel potent and safe anti-Babesia and anti-Theileria agents for the control of animal piroplasmosis. In the present study, we evaluated the inhibitory effects of Malaria Box (MBox) compounds (n = 8) against the growth of Babesia microti in mice and conducted bioinformatics analysis between the selected hits and the currently used antibabesial drugs, with far-reaching implications for potent combinations. METHODS: A fluorescence assay was used to evaluate the in vivo inhibitory effects of the selected compounds. Bioinformatics analysis was conducted using hierarchical clustering, distance matrix and molecular weight correlation, and PubChem fingerprint. The compounds with in vivo potential efficacy were selected to search for their target in the piroplasm parasites using quantitative PCR (qPCR). RESULTS: Screening the MBox against the in vivo growth of the B. microti parasite enabled the discovery of potent new antipiroplasm drugs, including MMV396693 and MMV665875. Interestingly, statistically significant (P < 0.05) downregulation of cysteine protease mRNA levels was observed in MMV665875-treated Theileria equi in vitro culture in comparison with untreated cultures. MMV396693/clofazimine and MMV665875/atovaquone (AV) showed maximum structural similarity (MSS) with each other. The distance matrix results indicate promising antibabesial efficacy of combination therapies consisting of either MMV665875 and AV or MMV396693 and imidocarb dipropionate (ID). CONCLUSIONS: Inhibitory and hematology assay results suggest that MMV396693 and MMV665875 are potent antipiroplasm monotherapies. The structural similarity results indicate that MMV665875 and MMV396693 have a similar mode of action as AV and ID, respectively. Our findings demonstrated that MBox compounds provide a promising lead for the development of new antibabesial therapeutic alternatives.


Subject(s)
Babesia microti , Babesiosis , Cysteine Proteases , Malaria , Theileria , Animals , Atovaquone/pharmacology , Atovaquone/therapeutic use , Babesiosis/drug therapy , Babesiosis/parasitology , Clofazimine/pharmacology , Clofazimine/therapeutic use , Cysteine Proteases/pharmacology , Drug Repositioning , Imidocarb/analogs & derivatives , Mice , Theileria/physiology
2.
J Adv Vet Anim Res ; 9(2): 267-274, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35891656

ABSTRACT

Objective: The effect of Artemisia herba-alba methanolic extract monotherapy and combination therapies on the in vitro growth of several Babesia and Theileria parasites in vitro and mice was investigated in this study. Materials and Methods: Fluorescence assay using SYBR Green I stain was used to evaluate the antibabesial efficacy inhibitory of A. herba-alba either in vitro or in vivo. Hematological parameters in the treated mice were analyzed using a Celltac MEK-6450 computerized hematology analyzer. Results: Artemisia herba-alba reduced the growth of Babesia bovis, Babesia bigemina, Babesia divergens, Theileria equi, and Babesia caballi in vitro in a dose-dependent manner. The in vitro inhibitory impact of A. herba-alba on B. divergens and B. caballi cultures was amplified when combined with either diminazene aceturate (DA). In B. microti-infected mice, a combination therapy consisting of A. herba-alba and a low DA dose inhibited B. microti growth significantly (p < 0.05) better than treatment with 25 mg kg-1 DA. Conclusions: These data show that A. herba-alba, when paired with a modest DA dose, could be a promising medicinal plant for babesiosis treatment.

3.
J Parasitol Res ; 2022: 8574541, 2022.
Article in English | MEDLINE | ID: mdl-35774222

ABSTRACT

Pomegranate (Punica granatum) peel has seen a rapid surge in attention as a medical and nutritional product over the last decade. The impact of pomegranate peel methanolic extract monotherapy and combination therapy on the in vitro growth of Babesia (B.) bovis, B. bigemina, B. divergens, B. caballi, and Theileria (T.) equi, as well as B. microti in mice, was investigated in this work. Fluorescence-based SYBR green I assay was used for evaluating the inhibitory antibabesial efficacy of pomegranate (Punica granatum) peel against the growth of several piroplasm parasites in vitro and in vivo. Celltac α MEK-6450 computerized haematology analyzer was used for monitoring the haematological parameters of treated mice every 4 days. Pomegranate peel inhibited the in vitro growth of B. bovis, B. bigemina, B. divergens, T. equi, and B. caballi in a dose-dependent manner, with IC50 values of 154.45 ± 23.11, 40.90 ± 9.35, 72.71 ± 14.77, 100 ± 16.20, and 77.27 ± 16.94 µg/ml, respectively. On a B. bovis culture, the in vitro inhibitory effect of pomegranate peel was amplified when it was combined with diminazene aceturate (DA). Combination therapy of pomegranate peel and a low dose of DA (15 mg kg-1) inhibited B. microti growth significantly (P < 0.05) higher than the treatment with the full dose of DA (25 mg kg-1) in B. microti-infected mice. These findings suggest that pomegranate peel might be a potential medicinal plant for babesiosis treatment, especially when combined with a low dosage of DA.

4.
J Vet Med Sci ; 84(7): 890-897, 2022 Jul 01.
Article in English | MEDLINE | ID: mdl-35527016

ABSTRACT

This study was organized to investigate the prevalence, antibiotic and disinfectant resistance phenotypes and genotypes as well as plasmid profiles of Shigella species isolated from raw cow milk and milk products in Egypt. Genotypic analysis was performed to determine the presence of ß-lactamase encoding genes (blaTEM, blaCTX-M, blaOXA-1 and blaSHV), tet(A) and qacE∆. Forty-two (7%) Shigella isolates (S. dysenteriae, S. flexneri, and S. sonnei) were recovered, with S. dysenteriae as the predominant type. Antibiotic sensitivity tests showed that 71.4% of Shigella isolates were resistant to three or more antibiotic classes (multidrug-resistant). High resistance rates were observed against tetracyclines (100%), ampicillin, amoxicillin-clavulanate (90.5%, each) and cefaclor (66.7%), while no resistance was detected against imipenem, sulfamethoxazole/trimethoprim, and azithromycin. Disinfectant susceptibility test of Shigella isolates revealed resistance to phenolic compound (vanillic acid), while 85.7% of the Shigella isolates were resistant to benzalkonium chloride. Uniplex PCR analysis declared the existence of ß-lactamase encoding genes (blaTEM in all isolates and blaCTX-M in 28.6% of isolates) and, tet(A) in all isolates and 85.7% of the isolates were positive for qacE∆1, while all isolates were negative for blaOXA-1 and blaSHV. All Shigella extended spectrum ß-lactamases (ESBL) producers (12, 100%) were positive for the blaTEM, blaCTX-M, and qacE∆1 genes. Furthermore, plasmid profiling revealed seven distinct plasmid patterns (P1-P7), ranging from 1.26 to 33.61 kb, among all the Shigella strains; S. dysenteriae exhibited the greatest variance. The co-transfer of ß-lactamase genes (blaTEM and blaCTX-M) and qacE∆1 genes was observed by conjugation from all ESBL producers to a recipient strain. These findings indicate the emergence of Shigella species in Egypt that exhibited multi-resistance to either antibiotics (particularly ESBL producer strains) or disinfectants. Thus, the resistance of Shigella species should regularly be monitored and appropriate measures should be taken to manage this problem.


Subject(s)
Milk , Shigella , Animals , Anti-Bacterial Agents/pharmacology , Cattle , Disinfectants , Egypt , Female , Microbial Sensitivity Tests/veterinary , Milk/microbiology , Shigella/drug effects , Shigella/genetics , beta-Lactamases/genetics
5.
Ticks Tick Borne Dis ; 13(2): 101904, 2022 03.
Article in English | MEDLINE | ID: mdl-35091295

ABSTRACT

Equine piroplasmosis is a tick-transmitted disease that is considered one of the most serious infectious diseases affecting equines. Searching for novel antipiroplasm drugs remains indispensable due to the emergence and spreading of resistant piroplasm parasites against the limited currently used drugs, diminazene aceturate and imidocarb dipropionate. Therefore, novel drugs with specified targets need to be identified and exploited. The inhibitory effects of Medicines for Malaria Venture (MMV) Malaria Box compounds with potent in vitro anti-equine piroplasmosis activity were evaluated against the growth of B. microti in mice in this study. Using a nested PCR assay targeting the B. microti ss-rRNA gene, we investigated the far-reaching impacts of effective combinations to inhibit parasite recrudescence. Using real-time PCR, this study revealed potential targets for the found potent compounds. When used as monotherapy, screening the Malaria Box against the in vivo growth of the B. microti parasite resulted in the discovery of new, potent antipiroplasm medicines, such as MMV020275 and MMV020490. In MMV020275-treated Theileria equi in vitro culture, a statistically significant difference (P<0.05) in the cGMP-dependent protein kinase (PKG) mRNA level was identified as a down-regulation in contrast to non-treated cultures. In conclusion, new potent antipiroplasm drugs, including MMV020275 and MMV020490 are identified. MMV020275 significantly down-regulate the mRNA levels of the PKG gene. Clofazimine enhanced the inhibitory efficacy of MMV compounds which is suggested to use in treatment of animal or human babesiosis in the future.


Subject(s)
Babesia , Babesiosis , Horse Diseases , Malaria , Theileria , Theileriasis , Animals , Babesia/genetics , Babesiosis/drug therapy , Babesiosis/parasitology , Cattle , Horse Diseases/drug therapy , Horse Diseases/parasitology , Horses , Mice , Real-Time Polymerase Chain Reaction , Theileria/genetics , Theileriasis/parasitology
6.
Mol Biochem Parasitol ; 247: 111444, 2022 01.
Article in English | MEDLINE | ID: mdl-34933065

ABSTRACT

Here, we have evaluated the inhibitory effects of Medicines for Malaria Venture (MMV) Malaria Box compounds that exhibited potent in vitro anti-bovine Babesia efficacy against the growth of B. microti in mice and conducted follow-up investigations of the structural similarity between the identified potent MMV compounds and the commonly used antibabesial drugs was performed using atom Pair fingerprints (APfp). Screening the Malaria Box against the in vivo growth of the B. microti parasite helped with the discovery of new, effective anti-bovine Babesia drugs, including MMV667488, MMV007285, and MMV019881. Of note, MMV019881 exhibited the highest anti-B. microti efficacy in vivo among the screened MMV compounds. The APfp results revealed that the maximum structural similarity (MSS) was observed between MMV007285, diminazene aceturate, and imidocarb dipropionate (ID). In the same way, clofazimine (CF) and MMV667488 showed the MSS with either each other based on the analysis. The distance matrix and molecular weight correlation findings highlight the possible potential antibabesial efficacy of MMV667488, ID, and CF when administrated as a combination therapy. In conclusion, in the current study new potent antibabesial drug, MMV019881 was identified. CF and MMV667488 showed the MSS with either each other based on the hierarchical clustering analysis (HCA) and such relation is confirmed by the distance matrix and molecular weight correlation findings. Such combination therapy might have a potential as a novel regime for treating animal or human babesiosis.


Subject(s)
Babesia microti , Babesia , Babesiosis , Malaria , Theileria , Animals , Babesiosis/drug therapy , Babesiosis/parasitology , Cattle , Computational Biology , Mice
7.
Sci Total Environ ; 650(Pt 2): 2063-2073, 2019 Feb 10.
Article in English | MEDLINE | ID: mdl-30290348

ABSTRACT

Fipronil (FPN), a commonly used phenylpyrazole pesticide can induce oxidative tissue damage following hazard usage. Due to the extensive household and commercial usage of FPN, its toxic effects on mammals received considerable attention. Finding the proper antioxidant that can overcome FPN-induced damage is essential. Therefore, the present study aimed to assess the hepatorenal ameliorative outcomes of N-acetyl cysteine (NAC) and taurine (TAU) against hepatorenal damage induced by FPN in male Wistar rats. Compared to control rats, oral FPN (at a dose of 19.4 mg kg-1 BW for five successive days) significantly increased serum activities (p ≤ 0.05) of alkaline phosphatase, lactate dehydrogenase and transaminases, in addition to total cholesterol, urea and creatinine levels. Moreover, FPN provoked oxidative damage indicated by increased malondialdehyde and nitric oxide formation and decreased glutathione concentration and activities of enzymatic antioxidants (superoxide dismutase, glutathione peroxidase and catalase) in the hepatic and renal tissues. Furthermore, FPN administration induced overexpression of the proapoptotic (Bax), while it downregulated the expression of the anti-apoptotic (Bcl-2) protein. Interestingly, oral administration of TAU (50 mg Kg-1 BW) and NAC (50 mg Kg-1 BW), alone or in combination, five days prior to and five days along with FPN administration, significantly ameliorated (p ≤ 0.05) and normalized the harmful effects of FPN on serum biomarkers of hepatorenal injury, lipid peroxidation and tissue antioxidants. In conclusion, TAU and NAC, alone or in combination, provided significant hepatorenal protection against oxidative stress and apoptosis induced by FPN.


Subject(s)
Acetylcysteine/pharmacology , Insecticides/toxicity , Protective Agents/pharmacology , Pyrazoles/toxicity , Taurine/pharmacology , Animals , Antioxidants/metabolism , Apoptosis/drug effects , Gene Expression/drug effects , Genetic Markers , Kidney/drug effects , Kidney/metabolism , Liver/drug effects , Liver/enzymology , Male , Rats , Rats, Wistar
8.
Int J Mol Sci ; 19(2)2018 Jan 24.
Article in English | MEDLINE | ID: mdl-29364179

ABSTRACT

Recent experiments showed a potential cardiotoxic effect of the macrolide antibiotic (tulathromycin). This study was performed to investigate whether diclofenac sodium (DFS) potentiates the cardiotoxicity of tulathromycin and increases the cardioprotective effects of lycopene against DFS and tulathromycin. Seven groups (eight per group) of adult Swiss albino mice received saline (control), tulathromycin (a single subcutaneous dose of 28 mg/kg/bw on day 14), DFS (a single oral dose of 100 mg/kg/bw on day 14), tulathromycin plus DFS, or lycopene (oral, 10 mg/kg/bw daily for 15 d) combined with tulathromycin, DFS, or both. Compared to the control group, the administration of tulathromycin or DFS (individually or in combination) caused significantly elevated (p < 0.05) serum levels of Creatine kinase-myocardial B fraction (CK-MB), lactate dehydrogenase, and cardiac-specific troponin-T and tissue levels of nitric oxide and malondialdehyde that were accompanied by significantly decreased tissue reduced glutathione content and glutathione peroxidase, superoxide dismutase, and catalase antioxidant enzyme activity. Upon histopathological and immunohistochemical examination, the mean pathology scores and the percentages of caspase-3-, Bax-, and CK-positive regions were significantly higher in the tulathromycin- and/or DFS-treated groups than in control mice. For all these parameters, the pathological changes were more significant in the tulathromycin-DFS combination group than in mice treated with either drug individually. Interestingly, co-administration of lycopene with tulathromycin and/or DFS significantly ameliorated the changes described above. In conclusion, DFS could potentiate the cardiotoxic effects of tulathromycin, whereas lycopene can serve as a cardioprotective agent against DFS and tulathromycin.


Subject(s)
Carotenoids/pharmacology , Diclofenac/adverse effects , Disaccharides/adverse effects , Heart/drug effects , Heterocyclic Compounds/adverse effects , Myocardium/metabolism , Protective Agents/pharmacology , Animals , Biomarkers/blood , Cardiotoxicity , Creatine Kinase, MB Form , Immunohistochemistry , L-Lactate Dehydrogenase/blood , Lipid Peroxidation/drug effects , Lycopene , Male , Mice
9.
Sci Rep ; 7(1): 12774, 2017 10 16.
Article in English | MEDLINE | ID: mdl-29038534

ABSTRACT

In this study, we evaluated the validity of a fluorescence-based assay using SYBR Green I (SG I) stain for screening antibabesial compounds against B. microti in mice. Two different hematocrits (HCTs; 2.5% and 5%) were used. Correlating relative fluorescence units (RFUs) with parasitemia showed significant linear relationships with R2 values of 0.97 and 0.99 at HCTs of 2.5% and 5%, respectively. Meanwhile, the Z' factors in a high-throughput screening (HTS) assay were within the permissible limit (≥0.5) at 2.5% HCT and lower than this value at 5% HCT. Taken together, the highest signal-to-noise (S/N) ratios were obtained at 2.5% HCT; therefore, we concluded that 2.5% was the best HCT for applying fluorescence assay in antibabesial drug screening in mice. Additionally, positive control mice and those treated with diminazene aceturate, pyronaridine tetraphosphate, and an allicin/diminazene aceturate combination showed peak parasitemia and fluorescence values on the same day post-inoculation. Moreover, using different concentrations of SG I revealed that the optimal concentration was 2x. In summary, considering that all experiments were applied under optimal laboratory conditions, fluorescence assay at 2.5% HCT using 2x SG I for B. microti parasite offers a novel approach for drug screening in mice.


Subject(s)
Antiprotozoal Agents/pharmacology , Babesia/drug effects , Drug Evaluation, Preclinical , High-Throughput Screening Assays/methods , Anemia/drug therapy , Anemia/parasitology , Animals , Benzothiazoles , Diamines , Diminazene/analogs & derivatives , Diminazene/pharmacology , Diminazene/therapeutic use , Drug Therapy, Combination , Female , Fluorescence , Hematocrit , Leukocytes/drug effects , Leukocytes/metabolism , Mice, Inbred BALB C , Naphthyridines/pharmacology , Naphthyridines/therapeutic use , Nucleic Acids/metabolism , Organ Specificity/drug effects , Organic Chemicals/metabolism , Parasites/drug effects , Parasites/metabolism , Quinolines , Reproducibility of Results
10.
J Vet Med Sci ; 79(7): 1301-1309, 2017 Jul 28.
Article in English | MEDLINE | ID: mdl-28603214

ABSTRACT

Platelet-rich plasma (PRP) has an important role in musculoskeletal surgery; however, it has been underutilized for accelerating the healing of abdominal wall defects in veterinary practice. Therefore, the aim of this study was to evaluate the use of commercial polyester/cotton fabric (Damour) as a new composite mesh for the repair of experimentally induced abdominal wall defects in canine models, and to investigate the possible role of PRP for improving such repair and reducing allied complications. For this purpose, abdominal wall defects were created in 24 healthy mongrel dogs and then repaired with mesh alone (control group) or mesh and allogenic PRP (PRP group). Dogs were euthanized after 2 or 4 months for gross examination of implantation site, detection of adhesion score and hernia recurrence. Moreover, tissue samples were collected for histological and gene expression analyses for neovascularization, collagen formation and tissue incorporation. Hernia recurrence was not recorded in PRP-treated dogs that also displayed significantly more neovascularization and less severe adhesion to the underlings (1.08 ± 0.51) in comparison to control group (2.08 ± 0.99). Histological and molecular evaluation confirmed the gross findings that collagen deposition, new vessel formation, and overexpression of angiogenic and myofibroplastic genes (COL1α1, COL3α1, VEGF and TGFß1) were observed more frequently in the PRP group, at both time points. In conclusion, we found that addition of allogenic PRP to Damour mesh enhanced neovessel formation, and increased tissue deposition and incorporation, with subsequent reduction of peritoneal adhesion and recurrence rate.


Subject(s)
Abdominal Wall/surgery , Dogs/surgery , Surgical Mesh/veterinary , Animals , Cotton Fiber , Disease Models, Animal , Platelet-Rich Plasma/metabolism , Polyesters , Wound Healing
SELECTION OF CITATIONS
SEARCH DETAIL
...